Repligen (RGEN) Cash & Equivalents (2010 - 2026)

Repligen (RGEN) has reported Cash & Equivalents for 17 consecutive years, with $810.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 14.33% year-over-year to $810.4 million in Q2 2026; TTM through Jun 2026 was $810.4 million, a 14.33% increase from a year earlier, with the FY2025 full-year figure at $767.6 million, up 1.32% from the prior year.
• Cash & Equivalents was $810.4 million for Q2 2026 at Repligen, up from $784.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $810.4 million in Q2 2026 and troughed at $516.6 million in Q1 2023.
• A 5-year average of $690.5 million and a median of $728.8 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slipped 18.77% in 2022 and soared 51.1% in 2024, its largest moves.
• Over 5 years, Cash & Equivalents stood at $523.5 million in 2022, then soared by 43.53% to $751.3 million in 2023, then rose by 0.84% to $757.6 million in 2024, then climbed by 1.32% to $767.6 million in 2025, then climbed by 5.58% to $810.4 million in 2026.
• The last three Cash & Equivalents figures came in at $810.4 million (Q2 2026), $784.5 million (Q1 2026), and $767.6 million (Q4 2025), per Business Quant data.